EgyptTuberculosis profile
Population  2015 92 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.22 (0.2–0.24) 0.24 (0.21–0.26)
Mortality (HIV+TB only) 0.018 (0.012–0.025) 0.02 (0.01–0.03)
Incidence  (includes HIV+TB) 13 (12–15) 15 (13–16)
Incidence (HIV+TB only) 0.053 (0.042–0.065) 0.06 (0.05–0.07)
Incidence (MDR/RR-TB)** 2.2 (1.8–2.6) 2.4 (2–2.8)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.58 (0.31–0.86) 4.4 (3.2–5.6) 5 (3.5–6.4)
Males 0.77 (0.54–1) 7.6 (6–9.2) 8.4 (6.6–10)
Total 1.4 (1–1.7) 12 (11–13) 13 (12–15)
TB case notifications, 2015  
Total cases notified 8 155
Total new and relapse 7 860
          - % tested with rapid diagnostics at time of diagnosis 10%
          - % with known HIV status 23%
          - % pulmonary 63%
          - % bacteriologically confirmed among pulmonary 82%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 59% (53–65)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.02 (0.02–0.02)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 14 <1%
          - on antiretroviral therapy 14 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  790
(670–900)
Estimated % of TB cases with MDR/RR-TB 14% (12–16) 23% (20–27)  
% notified tested for rifampicin resistance 13% 60% 1 517
MDR/RR-TB cases tested for resistance to second-line drugs   3
Laboratory-confirmed cases MDR/RR-TB: 210, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 107, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 84% 7 177
Previously treated cases, excluding relapse, registered in 2014 56% 290
HIV-positive TB cases, all types, registered in 2014   0
MDR/RR-TB cases started on second-line treatment in 2013 57% 60
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
18% (16–20)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data